Tamoxifen-induced thrombocytopenia

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 22, Issue 5, 1999, Pages 529-532

  Yao, James C ^a   Thomakos, Nikolaos ^b   McLaughlin, Peter ^a   Buchholz, Thomas A ^a   Kudelka, Andrzej P ^a   Wogan, Christine F ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Breast cancer; Tamoxifen; Thrombocytopenia

Indexed keywords

ANASTROZOLE; TAMOXIFEN;

ADULT; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CASE REPORT; DRUG EFFECT; FEMALE; HUMAN; THROMBOCYTE COUNT; THROMBOCYTOPENIA;

ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; CLINICAL TRIALS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; INCIDENCE; MIDDLE AGED; TAMOXIFEN; THROMBOCYTOPENIA;

EID: 0033503576     PISSN: 02773732     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000421-199910000-00022     Document Type: Article

References (15)

1. Physicians' Desk Reference. 53rd ed. Montvale, NJ: Medical Economics Company; 1999:3425-8.
2. McEvoy GK, ed. AHFS Drug Information. Bethesda, MD: American Society of Health System Pharmacists; 1998:935-7.
3. Nolvadex Professional Information Brochure NL1204 Rev T, October 1998. Wilmington, DE: Zeneca Pharmaceuticals, 1998.
4. Fisher B, Constantino JP, Wickerham DL, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst 1998;90:1371-88.
5. Candido A, Bussa S, Tartaglione R, et al. Tamoxifen-induced immune-mediated platelet destruction: a case report. Tumori 1993; 79:231-4.
6. Lerner HJ, Band PR, Israel L, Leung BS. Phase II study of tamoxifen: report of 74 patients with stage IV breast cancer. Cancer Treat Rep 1976;60:1431-5.
7. Tormey DC, Simon RM, Lippman ME, et al. Evaluation of tamoxifen dose in advanced breast cancer: a progress report. Cancer Treat Rep 1976;60:1451-5.
8. Henningsen J, Amberger H. Anti-oestrogen treatment of metastasizing carcinoma of the breast. Dtsch Med Wochenschr 1977;102: 713-6.
9. De Lena M, Brambilla C, Jirillo A. Tamoxifen efficacy in advanced breast cancer previously treated with endocrine and cytotoxic therapy. Tumori 1980;66:339-48.
10. Semiglasov VF, Ghershanovich ML, Kondratyev VB, Moiseyenko VM. Application of tamoxifen in treatment of disseminated and localized breast cancer [in Russian]. Vopr Onkol 1984;30:39-43.
11. Bliss JM, Wils J, Blijham G, et al. Toxicity analysis of a randomized trial comparing tamoxifen versus tamoxifen plus epirubicin in postmenopausal patients with node-positive breast cancer. Ann Oncol 1990;1(Suppl):20.
12. Farina G, Mantica C, Lverde N, et al. Toxicity of long-term adjuvant treatment with tamoxifen in breast cancer [abstract]. Proc Am Soc Clin Oncol 1995;14:139. Abstract 257.
13. Fisher B, Constantino J, Redmond C, et al. A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor - positive tumors. N Engl J Med 1989;320:479-84.
14. Cummings JF, Gray R, Davis TE, et al. Adjuvant tamoxifen treatment of elderly women with stage II breast cancer. Ann Intern Med 1985;103:324-9.
15. Jordan VC, ed. Tamoxifen for the treatment and prevention of breast cancer. Melville, NY: PRR, 1999.